Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands
- PMID: 23663128
- DOI: 10.1111/tbj.12125
Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands
Abstract
There is little information available on the patterns of chemotherapy regimens administered in daily practice to patients with early stage and metastatic or recurrent breast cancer. To determine the trends in type of chemotherapy regimens used in breast cancer patients, newly diagnosed breast cancer patients in the period 2000-2008 who received chemotherapy were identified from the Eindhoven Cancer Registry (ECR) and linked to the PHARMO RLS, including data on, e.g., in- and outpatient drug use. Chemotherapy regimens were classified based on the received combinations and sequences. Trends in the distribution of adjuvant chemotherapy regimens (for early-stage breast cancer) and palliative chemotherapy regimens (for metastatic or recurrent breast cancer) were determined and stratified by Her2/neu status when possible. In this study, 422 patients diagnosed with early-stage breast cancer received adjuvant chemotherapy. The use of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) decreased from 90% in 2000 to almost none since 2005. Administration of regimens that included anthracyclines increased from 4% in 2000 to 96% in 2005, but decreased to 68% in 2008. The use of trastuzumab- and taxane-containing regimens (with or without anthracyclines) increased from 2005 onwards to 24% and 34%, respectively, in 2008. Among the 82 breast cancer patients who received palliative chemotherapy at diagnosis or after breast cancer recurrence, the use of CMF and anthracyclines (without taxanes) decreased, while the use of taxanes (with or without anthracyclines) increased (26% in 2008). Trastuzumab was used as palliative chemotherapy from 2003 onwards, with 22% of the metastatic breast cancer patients receiving trastuzumab-containing regimens in 2008, and bevacizumab was administered since 2007 with 19% of the patients receiving bevacizumab-containing regimens in 2008. In conclusion, major changes have taken place in the chemotherapeutic treatment of patients with early and recurrent breast cancer. These changes reflect the key findings from large clinical trials, as incorporated in the Dutch guidelines.
Keywords: anthracyclines; breast cancer; chemotherapy regimen; population based; taxanes; trastuzumab; trend.
© 2013 Wiley Periodicals, Inc.
Similar articles
-
Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.Anticancer Res. 2011 Sep;31(9):3041-6. Anticancer Res. 2011. PMID: 21868556
-
[Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].Magy Onkol. 2002;46(4):307-13. Epub 2003 Feb 1. Magy Onkol. 2002. PMID: 12563352 Review. Hungarian.
-
HER2 over-expression and response to different chemotherapy regimens in breast cancer.J Zhejiang Univ Sci B. 2008 Jan;9(1):5-9. doi: 10.1631/jzus.B073003. J Zhejiang Univ Sci B. 2008. PMID: 18196606 Free PMC article.
-
[Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].Clin Ter. 2009;160(6):489-97. Clin Ter. 2009. PMID: 20198293 Italian.
-
The role of anthracyclines in the treatment of early breast cancer.J Oncol Pharm Pract. 2015 Jun;21(3):201-12. doi: 10.1177/1078155214531513. Epub 2014 Apr 26. J Oncol Pharm Pract. 2015. PMID: 24769570 Review.
Cited by
-
Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients.BMJ. 2015 Oct 6;351:h4901. doi: 10.1136/bmj.h4901. BMJ. 2015. PMID: 26442924 Free PMC article.
-
A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.Oncotarget. 2017 Mar 22;8(44):75864-75873. doi: 10.18632/oncotarget.16439. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100275 Free PMC article.
-
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.Springerplus. 2016 Mar 31;5:395. doi: 10.1186/s40064-016-2008-9. eCollection 2016. Springerplus. 2016. PMID: 27047721 Free PMC article.
-
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.Breast Cancer Res Treat. 2016 May;157(1):145-56. doi: 10.1007/s10549-016-3790-3. Epub 2016 Apr 23. Breast Cancer Res Treat. 2016. PMID: 27107569 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous